Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 8/20 | 0.39 |
| ▸ | FNTB | P49356 | 8/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | MARS1 | P56192 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5617582 | 0.91 | RNPEP (0.42) | ANPEPENPEPRNPEPMETAP2METAP1 | |
| SCHEMBL162031 | 0.91 | RNPEP (0.42) | ANPEPENPEPRNPEPMETAP2METAP1 | |
| SCHEMBL6045793 | 0.91 | RNPEP (0.42) | ANPEPENPEPRNPEPMETAP2METAP1 | |
| SCHEMBL20996747 | 0.91 | RNPEP (0.42) | ANPEPENPEPRNPEPMETAP2METAP1 | |
| SCHEMBL2418306 | 0.89 | ANPEP (0.42) | ANPEPENPEPRNPEPFNTAFNTB | |
| SCHEMBL11531701 | 0.84 | RNPEP (0.37) | ANPEPENPEPRNPEPMETAP2METAP1 | |
| SCHEMBL7263576 | 0.84 | RNPEP (0.37) | ANPEPENPEPRNPEPMETAP2METAP1 | |
| SCHEMBL2804079 | 0.84 | METAP2 (0.40) | ANPEPENPEPRNPEPMETAP2METAP1 | |
| SCHEMBL28729561 | 0.84 | METAP2 (0.43) | ANPEPENPEPRNPEPMETAP2METAP1 | |
| SCHEMBL6019778 | 0.84 | RNPEP (0.37) | ANPEPENPEPRNPEPMETAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019118370-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR PRODUCING FLOCCULENT MATERIALS FOR SPECIAL EFFECTS | XOTRAMORPHIC, LLC (US) | 2019-06-20 | — | — | WO | claimed |
| CN-1315532-C | Compound lysoamidase spray agent and preparing method | SHANGHAI NEW MEDICINE RES AND (CN) | 2007-05-16 | — | — | CN | claimed |
| CN-1616092-A | Compound lysoamidase spray agent and preparing method | SHANGHAI NEW MEDICINE RES AND (CN) | 2005-05-18 | — | — | CN | claimed |
| WO-2004035764-A2 | PROTEIN SYNTHESIS WITH TANDEMLY ACTIVATED tRNAs | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2004-04-29 | — | — | WO | claimed |
| US-20040002542-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-01-01 | — | — | US | claimed |
| US-20020198378-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2002-12-26 | — | — | US | claimed |
| US-5602119-A | TREATMENT OF HIV AND AIDS | G. D. SEARLE & CO. | 1997-02-11 | — | — | US | claimed |
| EP-0666841-B1 | SUCCINOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1997-01-22 | — | — | EP | claimed |
| EP-0666841-A1 | SUCCINOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS. | SEARLE & CO (US) | 1995-08-16 | — | — | EP | claimed |
| WO-1994010133-A1 | SUCCINOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-05-11 | — | — | WO | claimed |
| US-5151521-A | 1-aminoethyl phosphonic acid derivatives | MERCK & CO., INC. (US) | 1992-09-29 | — | — | US | claimed |
| EP-0175871-B1 | PROCESS FOR IMPROVING OR MODIFYING THE TASTE AND AROMA OF CITRUS FRUIT COMPOSITIONS | FIRMENICH SA (CH) | 1988-03-23 | — | — | EP | claimed |
| EP-0175871-A1 | Process for improving or modifying the taste and aroma of citrus fruit compositions | FIRMENICH SA (CH) | 1986-04-02 | — | — | EP | claimed |
| WO-2024081864-A1 | INHIBITORS OF NT5C2 AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024076610-A2 | INHIBITORS OF SPNS2 AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2024-04-11 | — | — | WO | disclosed |
| CN-117604091-A | Use of a biomarker detection product in the preparation of a product for aiding in the diagnosis, diagnosis or prognosis of a neural tube abnormality | 首都儿科研究所 | 2024-02-27 | — | — | CN | disclosed |
| WO-1994010133-A1 | SUCCINOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-05-11 | — | — | WO | disclosed |
| EP-0547065-A4 | MELANIN PRODUCTION BY TRANSFORMED MICROORGANISMS | — | 1993-09-15 | — | — | EP | disclosed |
| EP-0547065-A1 | MELANIN PRODUCTION BY TRANSFORMED MICROORGANISMS | Biosource Technologies, Inc. (US) | 1993-06-23 | — | — | EP | disclosed |
| WO-1992000373-A1 | MELANIN PRODUCTION BY TRANSFORMED MICROORGANISMS | BIOSOURCE GENETICS CORPORATION (CA) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198378-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | SUMO1, CHUK, SENP1 | ANPEP 60/4885ENPEP 88/4885RNPEP 121/4885 |
| US-20040002542-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | SUMO1, CHUK, SENP1 | ANPEP 60/4885ENPEP 88/4885RNPEP 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.